Skip to main content
Clinical Trials/CTRI/2022/07/043922
CTRI/2022/07/043922
Completed
未知

A comparative study in thrombocytopenia induced by dengue fever or viral fever between kiwi and guava - A Randomized Clinical Trial

ONE0 sites100 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: A90- Dengue fever [classical dengue]Health Condition 2: B978- Other viral agents as the cause ofdiseases classified elsewhere
Sponsor
ONE
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
September 30, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
ONE

Eligibility Criteria

Inclusion Criteria

  • Patients with thrombocytopenia (Low platelet count) induced by dengue fever or any other viral fever

Exclusion Criteria

  • Patients less than 5 years

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Platenza Tablets for Dengue fever
CTRI/2018/02/011789The Himalaya Drug Company40
Active, not recruiting
Phase 1
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.0Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-000114-19-GRGlaxoSmithKline Research and Development Ltd160
Active, not recruiting
Phase 1
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-000114-19-IEGlaxoSmithKline Research and Development Ltd160
Active, not recruiting
Phase 1
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-000114-19-CZGlaxoSmithKline Research and Development Ltd160
Active, not recruiting
Not Applicable
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-000114-19-NLGlaxoSmithKline Research and Development Ltd160